Jeffrey M. Leiden

2021 - Vertex Pharmaceuticals

In 2021, Jeffrey M. Leiden earned a total compensation of $8.2M as Executive Chairman at Vertex Pharmaceuticals, a 50% decrease compared to previous year.

Compensation breakdown

Salary$242,308
Stock Awards$7,875,259
Other$39,672
Total$8,157,239

Leiden received $7.9M in stock awards, accounting for 97% of the total pay in 2021.

Leiden also received $242.3K in salary and $39.7K in other compensation.

Rankings

In 2021, Jeffrey M. Leiden's compensation ranked 1,415th out of 12,397 executives tracked by ExecPay. In other words, Leiden earned more than 88.6% of executives.

ClassificationRankingPercentile
All
1,415
out of 12,397
89th
Division
Manufacturing
508
out of 5,492
91st
Major group
Chemicals And Allied Products
186
out of 2,367
92nd
Industry group
Drugs
155
out of 2,090
93rd
Industry
Pharmaceutical Preparations
104
out of 1,537
93rd
Source: SEC filing on April 7, 2022.

Leiden's colleagues

We found four more compensation records of executives who worked with Jeffrey M. Leiden at Vertex Pharmaceuticals in 2021.

2021

Reshma Kewalramani

Vertex Pharmaceuticals

Chief Executive Officer

2021

Stuart Arbuckle

Vertex Pharmaceuticals

Chief Operating Officer

2021

Nia Tatsis

Vertex Pharmaceuticals

EVP & Chief Regulatory and Quality Officer

2021

Charles Wagner

Vertex Pharmaceuticals

Chief Financial Officer

News

You may also like